Webinar Implications of EU FMD for pharmacists and staff



Register for this webinar to discuss the impact of the European Union’s Falsified Medicines Directive (EU FMD) on pharmacies in the UK and throughout Europe.


Tuesday, September 11th, 12PM GMT+1 or Tuesday, September 18th, 4PM GMT+1


  • Overview of the EU FMD and the February 2019 compliance deadline;
  • The responsibility of pharmacies regarding EU FMD;
  • Solutions that are available to help pharmacists and staff reach compliance;
  • Real-life customer issues and successes;
  • The potential for additional benefits beyond compliance.




A successful senior VP, Alan Birrell is a senior executive with experience in the Healthcare sector including medical devices, diagnostics, biological’s, pharmaceutical and ophthalmic products with progressive roles in sales, marketing, manufacturing, and executive management.

Alan’s role with OPTEL as Account Director United Kingdom will be to successfully leverage the OPTEL Group’s existing core business presence in the UK and successfully launch Optel Healthcare’s solution to address the upcoming EU Falsified Medicines Directive.

Contact Alan at [email protected]

Dhermita Desai’s operational skills have been honed through 16 years of work in the Life Sciences industry. Before coming to OPTEL, Dhermita worked as a serialisation programme manager for Concordia International, where she coordinated the Concordia International programme for implementation of serialisation across all defined markets and SKUs. Her responsibilities at Concordia included authoring validation documents and onboarding more than 100 trading partner CPOs and CMOs.

She has also held quality and program management roles at Amdipharm Mercury Company, Mercury Pharma, Lexon UK and Reckitt Benckiser Healthcare International. She views constantly evolving regulatory compliance mandates as tremendous opportunities to leverage her organizational and management skills to ensure that her clients’ serialization projects meet regulatory market and business requirements. Dhermita has a degree from De Montfort University in Pharmaceutical Chemistry.

About OPTEL Group

Certified B Corporation, OPTEL, is a leading multinational provider of traceability systems, and its mission is to create a better world through intelligent supply chains. The company’s renowned solutions ensure the quality of consumer health products and help stop counterfeiting of pharmaceuticals and medical devices throughout the world. OPTEL is also adapting its innovative technologies to create efficiencies in various other sectors ─ from health-related industries to smart manufacturing and more, all can benefit from traceability. With the recent acquisitions of Verify Brand and GeoTraceability, OPTEL is the only company to provide end-to-end traceability solutions, providing true visibility across the entire supply chain.  OPTEL’s expertise will allow diverse industries to measure, inspect, control and track a variety of elements to improve quality and make better use of resources. For more information, visit www.optelhealthcare.com

Optel will be attending the October ICCA conference in Edinburgh to provide further details and support for your EU FMD  journey.


About ICCA

The Independent Company Chemist Alliance (ICCA) was founded in 1992 to give privately owned regional multiples an open forum in which to debate, research and progress the local and national interests of community pharmacy. Some key objectives of members are; to co-operate on matters of good professional practice; to encourage pharmacy bodies to improve healthcare in local communities; to improve professional standards; to facilitate competition between contractors in the provision of healthcare services.As our environment continues to evolve so too will the objectives of the members.